BCM
HRTX icon

BlueCrest Capital Management’s Heron Therapeutics HRTX Stock Holding History

BlueCrest Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-68,434
Closed -$948K – 964
2017
Q2 		$948K Buy
+68,434
New +$991K 0.04% 472

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

BlueCrest Capital Management's HRTX Position: Q3 2017 in Review

BlueCrest Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2017, closing a stake of 68,434 shares — an estimated $948K sold.

BlueCrest Capital Management first reported a position in HRTX in Q2 2017 and held it in 1 quarter. The position peaked at $948K in Q2 2017. 104 funds tracked by Wall St. Rank hold HRTX as of Q3 2017.

  • BlueCrest Capital Management reported no remaining Heron Therapeutics position as of Q3 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 68,434 Heron Therapeutics shares in Q3 2017, an estimated $948K.
  • BlueCrest Capital Management first reported a position in Heron Therapeutics in Q2 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Heron Therapeutics position peaked at $948K in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2017.

Based on BlueCrest Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.